Updates in the Treatment of HR+ Breast Cancer : Episode 9

Opinion

Video

July 29, 2024

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

Author(s):

Kelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

EP: 1.Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

EP: 2.Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

EP: 3.Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

EP: 4.Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

EP: 5.Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

EP: 6.Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 7.Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

EP: 8.Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

EP: 9.Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

EP: 10.ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

EP: 11.Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

EP: 12.Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

Video content above is prompted by the following:

What are the other options for advanced HR+ disease(PI3K/AKT/mTOR inhibitors)?
- When and how are these being used? Are there any AEs of concern? How do you manage?
- ADCs

Related Videos

Ruth M. O’Regan, MD

2 KOLs are featured in this series.

Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine

5 KOLs are featured in this series.

5 KOLs are featured in this series.

5 KOLs are featured in this series.

Related Content

Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center

November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Breast Cancer

November 18th 2024

Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer

MedNews Week

September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com

November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center

November 7th 2024

AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

Related Content

Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center

November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Breast Cancer

November 18th 2024

Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer

MedNews Week

September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com

November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center

November 7th 2024

AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

Latest Conference Coverage

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.